This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 1998;279:346.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA is advising physicians about 2 new warnings in the labeling of mibefradil dihydrochloride (Posicor), a calcium channel blocker. One warning uses information from new reports to strengthen language in the labeling about the association between use of mibefradil and slowing or complete suppression of sinoatrial node activity. The supervening junctional rhythms have often been as slow as 30 to 40 beats per minute. Many of the reports have incorrectly identified the adverse event as complete AV block. The reports most commonly involved elderly patients, mainly in association with the concomitant use of -blockers. Care should be taken when combining mibefradil with -blockers. In patients with low heart rates, use of any combination of agents that can slow the sinus node or affect the AV node (eg, -blockers, digitalis, and the calcium channel blockers mibefradil, diltiazem hydrochloride, and verapamil) should in general be undertaken only after careful consideration, as . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Medical Consultant's Role in Caring for Patients with Hip Fracture
Morrison et al.
ANN INTERN MED 1999;130:76-77.
FULL TEXT